我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

缺血性心脏病心肌能量代谢障碍的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第2期
页码:
207-211,217
栏目:
综述
出版日期:
2018-02-15

文章信息/Info

Title:
Research progress in myocardial energy metabolism of ischemic heart disease
作者:
张 佩; 王承龙; 刘剑刚; 张大武; 于永慧
(中国中医科学院西苑医院心血管病中心、心血管病研究所，北京 100091)
Author(s):
ZHANG Pei;  WANG Cheng-long;  LIU Jian-Gang;  ZHANG Da-wu;  YU Yong-hui
(Cardiovascular Disease Center, Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences & Heart Institute of China Academy of Chinese Medical Sciences, Beijing 100091, China)
关键词:
缺血性心脏病; 能量代谢; 线粒体
Keywords:
ischemic heart disease;  energy metabolism;  mitochondrion
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
冠状动脉病变引起的心肌缺血（myocardial ischemia，MI）是导致心脏结构和功能发生改变的重要因素。同时，心肌组织的缺血、缺氧也是导致心肌细胞发生能量代谢障碍的主要原因，优化能量代谢的药物治疗也成为防治MI的治疗靶点和热点。心肌细胞的能量主要来源于线粒体内的三磷酸腺苷（Adenosine triphosphate,ATP），因此调节线粒体的生物合成是改善心肌能量代谢的重要途径，尤其是促进心肌组织的糖酵解和抑制游离脂肪酸氧化，有利于减轻MI引起的心肌细胞损伤，具有改善心肌组织功能。本文就缺血心肌的能量代谢机制和对其临床药物治疗的研究进展作简单归纳和综述。
Abstract:
The coronary artery lesion caused by myocardial ischemia (MI) is one of the important factors of cardiac structural changes and functional disorders. At the same time, the ischemia and hypoxia of myocardial tissue can also cause myocardial energy metabolism disorder. Drugs optimizing energy metabolism have become therapeutic targets and hot spots for the prevention and control of MI. As the energy of myocardial cells mainly comes from adenosine triphosphate (ATP) in mitochondria, adjusting the biosynthesis of mitochondria is an important way to improve myocardial energy metabolism, especially to promote glycolysis of myocardial tissue and inhibit the oxidation of free fatty acid, which are conducive to the reduction of the myocardial cell injury caused by MI and the improvement of the function of myocardial tissue. This article briefly summarizes and reviews the mechanism research of ischemic myocardial energy metabolism and also the research progress in clinical drug treatment.

参考文献/References

[1]Iqbal MN,Rao M,Khan N,et al.Non obstructive coronary artery disease in patients admitted for elective coronary angiography[J].Pak J Med Sci,2014,30(6):1336-1340.

[2]张 运,陈文强.缺血性心脏病发病机制的新观点[J].中华心血管病杂志,2014,42(2):94-97.

[3]Tuunanen H,Knuuti J.Metabolic remodelling in human heart failure[J]. Cardiovasc Res,2011,90(2):251-257.

[4]Neely JR,Morgan HE.Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle[J].Annu Rev Physiol,1974,36:413-459.

[5]Wong AP,Niedzwiecki A,Rath M.Myocardial energetics and the role of micronutrients in heart failure:a critical review[J].Am J Cardiovasc Dis,2016,6(3):81-92.

[6]E Levelt E,Rodgers C,Clarke WT,et al.Effect of exercise on myocardial energy metabolism and relationship between coronary microvascular dysfunction and abnormal myocardial energetics in diabetic cardiomyopathy[J].J Cardiovasc Magn Reson,2015,17(Suppl 1):98.

[7]Palaniswamy C,Mellana WM,Selvayaj DR,et al.Metabolic modulation: a new therapeutic target in treatment of heart failure[J].Am J Ther,2011,18(6):e197-e201.

[8]Lopaschuk GD,Ussher JR,Folmes CD,et al.Myocardial fatty acid metabolism in health and disease[J].Physiol Rev,2010,90:207-258.

[9]von Lewinski D,Gasser R,Rainer PP,et al.Functional effects of glucose transporters in human ventricular myocardium[J].Eur J Hear Fail,2010,12(20):106-113.

[10]Abel ED. Glucose transport in the heart[J].Front Biosci,2004,9:201-215.

[11]蔡琳婷，陈文新.心肌细胞葡萄糖转运蛋白4的转运调控及与心肌活力关系的研究进展[J].国际放射医学核医学杂志,2013,37(1):47-51.

[12]Magnoni LJ,Vraskou Y,Palstra AP,et al.AMP-activated protein kinase plays an important evolutionary conserved role in the regulatin of glucose metabolism in fish skeletal muscle cells[J].PLoS One,2012,7(2):e31219.

[13]Pehmoller C,Treebak JT,Birk JB,et al.Genetic disruption of AMPK signaling abolishes both contraction and insulin stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle[J].Am J Physiol Endocrinol Metab,2009,297(3):E665-E675.

[14]王 俊,李师耿,王 喻,等. 6-磷酸果糖激酶-2/果糖双磷酸酶-2同工酶3基因敲除小鼠模型的构建[J].中华实验外科杂志,2015,32(12):2986-2989.

[15]Luiken JJ,Dyck DJ,Han XX,et al.Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane embrane[J].Am J Physiol Endocrinol Metab,2002,282(2):E491-E495.

[16]Monaco C,Whitfield J,Jain SS,et al.Activation of AMPKα2 Is Not Reauired for Mitochondrial FAT/CD36 Accumulation during Exercise[J].PLoS One,2015,10(5):e0126122.

[17]Hrometz SL,Ebert JA,Grice KE,et al.Potentiation of Ecstasy-induced hyperthermia and FAT/CD36 expression in chronically exercised animals[J].Temperature(Austin),2016,3(4):557-566.

[18]Habets DD,Coumans WA,Voshol PJ,et al.AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36[J].Biochem Biophys Res Commun,2007,355(1):204-210.

[19]宋 杰,胡阳黔,刘 坚,等.黄芪多糖对慢性心衰大鼠心肌AMPK 活性和FFA 代谢的影响[J].中国病理生理杂志,2015,31(1),28-32.

[20]Reape TJ,Brogan NP,Mccabe PF.Mitochondrion and Chloroplast Regulation of Plant Programmed Cell Death[M]//Gunawardena AN,Mccabe PF.Plant Programmed Cell Death.Springer Internation Publishing,2015:33-53.

[21]Jager S,Handschin C,St-Pierre J,et al.AMP-activated protein kinase(AMPK)action -10-in skeletal muscle via direct phosphorylation of PGC-1alpha[J].Proc Natl Acad Sci USA,2007,104(29):12017-12022.

[22]Mootha VK,Handschin C,Arlow D,et al.Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle[J].Proc Natl Acad Sci USA,2004,101(17):6570-6575.

[23]Eisele PS,Salatino S,Sobek J,et al.The peroxisome proliferator-activated receptor γ coactivator 1α/β(PGC-1)coactivators repress the transcriptional activity of NF-κB in skeletal muscle cells[J].J Biol Chem,2013,288(4):2246-2260.

[24]Wu Z,Puigserver P,Andersson U,et al.Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1[J].Cell,1999,98(1):115-124.

[25]王 艳,黄德强,罗志军.AMPK 对线粒体功能的调节[J].中国细胞生物学学报,2013,35(10):1434-1443.

[26]Lee-Young RS,Bonner JS,Mayes WH,et al.AMP-activated protein kinase(AMPK)α2 plays a role in determining the cellular fate of glucose in insulin-resistant mouse skeletal muscle[J].Diabetologia,2013,56(3):608-617.

[27]Canto C,Jiang LQ,Deshmukh AS,et al.Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle[J].Cell Metab,2010,11(3):213-219.

[28]Gowans GJ,Hawley SA,Ross FA,et al.AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation[J].Cell metabolism,2013,18(4):556-566.

[29]Sodi-Pallares D,Testelli MR,Fishleder BL,et al.Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction -American Journal of Cardiology[J].Am J Cardiol,1962,9:166-181.

[30]殷仁富,陈金明,吴宗贵,等. 胰岛素促进狗缺血心肌葡萄糖转运子1 移位和葡萄糖摄取［J］. 基础医学与临床, 2001, 21(3):253-255.

[31]张小莉,赵小蕊. 极化液及1,6-二磷酸果糖治疗急性心肌损伤的疗效对比［J］. 中西医结合心脑血管病杂志, 2016, (16):1906-1907.

[32]Riedel BJ, Gal J, Ellis G, et al. Myocardial protection using fructose-1,6-diphosphate during coronary artery bypass graft surgery: a randomized, placebo-controlled clinical trial［J］. Anesth Analg, 2004, 98(1):20-29.

[33]Bhandari B, Subramanian L. Ranolazine. a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders［J］. Recent Pat Cardiovasc Drug Discov, 2007, 2(1):35-39.

[34]倪薇. 美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的疗效评价［J］. 中西医结合心血管病杂志, 2015, 3(1):91-92.

[35]贺春晖,马依彤,苏冉,等. 曲美他嗪治疗稳定型心绞痛疗效与安全性的系统评价［J］. 中国循证医学杂志, 2012, 12(6):700-707.

[36]Pekala J, Patkowska-Soko B, Bodkowski R, et al. L-carnitine--metabolic functions and meaning in humans life［J］. Curr Drug Metab, 2011, 12(7):667-678.

[37]王鑫路,陈亚丹,付秀娟. 左卡尼汀治疗心力衰竭疗效的Meta分析［J］. 中国药房, 2016, (27):3818-3821.

[38]李隆贵,胡琴,耿召华. 压力负荷性肥厚心肌脂肪酸代谢异常及卡维地洛干预效应［J］. 中华心血管病杂志, 2005, 33(增刊):323-324.

[39]刘伟卡. 维地洛联合依那普利对老年慢性心力衰竭的疗效的评价［J］. 医学综述, 2015, 21(6):1146-1148.

[40]Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexline corrects energy deficiency and improves exercise capacity in symptomatic hypertropic cardiomyopathy[J].Circulation,2010,122(16):1562-1569.

[41]Wang P,Fraser H,Lioyd SG,et al,A comparison between ranolazine and CVT-4325,a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion ［J］. J Pharmacol Exp Ther, 2007, 321(1):213-220.

[42]张祥宇,江力勤,蒋芬芳,等.雷诺嗪对大鼠急性心肌梗死早期左心室功能及梗死区心肌损伤的影响[J].心电与循环,2016,35(5):325-328.

备注/Memo

备注/Memo:
收稿日期：2016-11-22.基金项目：国家自然科学基金面上项目资助（81273934；81173384） 通讯作者：王承龙，教授，主要从事中西医结合心血管病研究 Email：wcl796@163.com 共同通讯作者：刘剑刚，研究员，主要从事心血管病基础和临床研究 Email：liujiangang2002@sina.com 作者简介：张佩，硕士生 Email：709522180@qq.com
更新日期/Last Update: 1900-01-01